San Diego Still Shines Despite VC Setbacks
This article was originally published in Start Up
The San Diego life sciences industry has endured several losses or setbacks by local venture capital firms yet its start-ups remain top recipients of capital.
You may also be interested in...
Investors in diagnostics and imaging companies are watching the values of their stakes rise following strong IPOs.
The age of specialization is not over for venture capital firms. The health care team from Pequot Ventures left the hedge-fund heavy firm to start Longitude Capital. Meanwhile, Enterprise Partners Venture Capital is said to be raising a health care only fund.
With a goal to focus on pediatric respiratory disease and allergy, several ex-Dura Pharmaceutical executives were able to attract $98 million in Series A funding without having technology, products, or IP. The company's June 2005 financing is another signal that investing in the highest-quality start-up biotechs is increasingly a game for VC firms with deep pockets.